Literature DB >> 7471315

Histopathological studies on antitumor effect of sporamycin. Cell-mediated immunity against allogeneic tumor-bearing mice.

Y Kawakubo, K Komiyama, I Umezawa, Y Nishiyama.   

Abstract

Mice that had received transplants of sarcoma-180 followed by treatment with sporamycin were examined histopathologically at periodic intervals. A marked degeneration of tumor cells was observed at an early stage after the administration of sporamycin, but the degeneration subsequently ceased and regrowth of the tumor was seen. Marked infiltration of lymphoid cells, granulation tissue, and fibrosis was seen in the stroma or surrounding tissue of the tumor at a late stage after the administration of sporamycin, and the regression of tumor cells became marked. With a few exceptions the mice were completely cured by about the 40th day. In the peripheral lymphoid tissues, a transitory decrease in the number of cells was observed after the administration of sporamycin, but this was followed by regeneration of the cells, followed by a marked increase in the B cell system. On the other hand, lymphoid cell depletion of the thymus had persisted. Transplantation of intact sarcoma-180 to mice preliminarily inoculated with sporamycin-treated sarcoma-180 cells resulted in inhibition of tumor growth in most of the mice, and qualitatively the same tissue reactions as those in mice cured of sarcoma-180 by sporamycin were seen. The results suggest that enhancement both of antigenicity of the tumor (cells) and of the subsequent immune response of the host by sporamycin may be involved in the cure of the experimental tumor.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7471315     DOI: 10.1007/bf00435414

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

Review 1.  Virsues and systemic lupus erythematosus.

Authors:  R S Schwartz
Journal:  N Engl J Med       Date:  1975-07-17       Impact factor: 91.245

2.  Antitumor activity of a new antitumor antibiotic, sporamycin.

Authors:  K Komiyama; H Takeshima; I Umezawa
Journal:  Gan       Date:  1977-04

3.  A new antitumor antibiotic, PO-357.

Authors:  I Umezawa; K Komiyama; H Takeshima; J Awaya; S Omura
Journal:  J Antibiot (Tokyo)       Date:  1976-11       Impact factor: 2.649

4.  Increased immunogenicity of TA3-Ha cells treated with the antitumor antibiotic macromomycin (B).

Authors:  E Coronetti; M M Lippman
Journal:  J Natl Cancer Inst       Date:  1976-06       Impact factor: 13.506

5.  A new antitumor antibiotic, sporamycin.

Authors:  K Komiyama; K Sugimoto; H Takeshima; I Umezawa
Journal:  J Antibiot (Tokyo)       Date:  1977-03       Impact factor: 2.649

Review 6.  Cooperating and controlling functions of thymus-derived lymphocytes in relation to autoimmunity.

Authors:  A C Allison; A M Denman; R D Barnes
Journal:  Lancet       Date:  1971-07-17       Impact factor: 79.321

7.  On the mode of action of BCG.

Authors:  M S Mitchell; D Kirkpatrick; M B Mokyr; I Gery
Journal:  Nat New Biol       Date:  1973-06-13

8.  Pathogenesis of autoimmunity in New Zealand mice. V. Loss of thymic suppressor function.

Authors:  A D Steinberg
Journal:  Arthritis Rheum       Date:  1974 Jan-Feb

9.  Tissue pharmacokinetics and inhibition of DNA synthesis in mice treated with sporamycin.

Authors:  K Komiyama; I Umezawa
Journal:  J Antibiot (Tokyo)       Date:  1978-05       Impact factor: 2.649

10.  Casein-induced experimental amyloidosis. V. The response of lymphoid organs to T and B mitogens.

Authors:  M A Scheinberg; M Bennett; E S Cathcart
Journal:  Lab Invest       Date:  1975-07       Impact factor: 5.662

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.